OraVerse Oral Anesthetic
Dr. Drew Vanderbrook is now offering OraVerse to patients who don’t want that lingering numbness after local anesthetics. After administrating OraVerse, a patient can return to normal sensation twice as fast. In clinical trials, patients have reported a return as quickly as 30 minutes after receiving OraVerse.
What is OraVerse?
OraVerse is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue numbness following routine dental procedures. The first-in-class product was officially launched earlier this year by the San Diego based company Novalar Pharmaceuticals, Inc.
The average duration of soft tissue numbness following the use of a local dental anesthetic is 3-5 hours. Numbness can lead to functional deficits. These deficits can result in difficulty with speaking, smiling, eating, drinking, biting of lip or cheek and uncontrolled drooling as well as give the patient a perceived sense of altered appearance. OraVerse has been proven to return a patient’s normal sensation twice as fast.
OraVerse has an excellent safety profile. There are no contraindications and no known drug interactions with OraVerse. In clinical trials involving over 700 patients, there was no significant difference in adverse events versus control.
OraVerse (phentolamine mesylate) Injection is the first and only local dental anesthesia reversal agent that accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. OraVerse is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is indicated for use only in adults and children 6 years of age or older and weighing at least 15 kg (33 lbs). For more information visit oraverse.com
Important Safety Information
Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease; as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.